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ABSTRACT
Mesenchymal stem cells (MSCs) therapy has limitations due
to the poor viability of MSCs after cell transplantation.
Integrin-mediated adhesion is a prerequisite for cell sur-
vival. As a novel anti-death strategy to improve cell survival
in the infarcted heart, MSCs were genetically modiﬁed to
overexpress integrin-linked kinase (ILK). The survival rate
of ILK-transfected MSCs (ILK-MSCs) was augmented by
about 1.5-fold and the phosphorylation of ERK1/2 and Akt
in ILK-MSCs were increased by about three and twofold,
respectively. ILK-MSCs demonstrated an increase of two-
fold in the ratio of Bcl-2/Bax and inhibited caspase-3 activa-
tion, compared with hypoxic MSCs. The adhesion rate of
ILK-MSCs also had a 32.2% increase on the cardiac ﬁbro-
blast-derived three-dimensional matrix and ILK-MSCs
showed higher retention by about fourfold compared to
unmodiﬁed MSCs. Six animals per group were used for the
in vivo experiments analyzed at 1 week after occlusion of
the left coronary artery. ILK-MSC transplanted rats had a
12.0% 6 3.1% smaller infarct size than MSC-treated rats
after ligation of left anterior descending coronary artery.
Transplantation of ILK-MSCs not only led to a 16.0% 6
0.4% decrease in the ﬁbrotic heart area, but also signiﬁ-
cantly reduced the apoptotic positive index by two-thirds
when compared with ligation only. The mean microvessel
count per ﬁeld in the infarcted myocardium of ILK-MSCs
group was increased relative to the sham group and
MSCs group. In conclusion, the ILK gene transduction of
MSCs further assisted cell survival and adhesion, and
improved myocardial damage when compared with MSC
only after transplantation. STEM CELLS 2009;27:1358–1365
Disclosure of potential conﬂicts of interest is found at the end of this article.
INTRODUCTION
As a consequence of myocardial infarction (MI), irreversible
tissue damage and physiologic dysfunction occur in the heart
[1]. The damaged myocytes in infarcted tissues undergo pro-
gressive replacement by ﬁbroblasts to form scar tissue which
may lead to remodeling of the left ventricle (LV) as a result
of a rise in mechanical wall stress [2]. Recent attempts to
repair infarcted hearts using alternative sources of cardiomyo-
cytes revealed that myogenic cells from various stem cells
replaced resident myocytes in cardiac tissue after injury [3].
In particular, mesenchymal stem cells (MSCs) have become
one of the most potent cell sources for repairing infarcted
myocardium because MSCs are multipotent cells capable of
differentiating into cardiac myocytes, endothelial cells, and
vascular smooth muscle cells both in vivo and in vitro under
the appropriate culture conditions [4–6]. Although MSCs rep-
resent a suitable source of autologous cells for cell therapy
focused on the improvement of cardiac function, MSC ther-
apy has limitations due to the poor viability of MSCs after
cell transplantation [7].
To overcome this limitation, antideath strategies may be
required to improve stem cell survival/number in the infarcted
heart [8]. The absence of adhesion is probably a main cause
of poor cell survival in cell transplantation. Cell adhesion to
the extracellular matrix (ECM) is mediated by integrins,
which control a variety of important processes including gene
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expression, proliferation, differentiation, and even survival
[9–13]. Integrin-linked kinase (ILK) is a 59-kDa Ser/Thr
kinase that binds to the cytoplasmic domain of b-integrin and
participates in the regulation of cell adhesion, growth, cell
shape change, and ECM assembly upstream of the Akt/protein
kinase B (PKB) and mitogen-activated protein (MAP) kinase
pathways [14–16].
In this study, we hypothesized that MSCs that were genet-
ically engineered to enhance adhesion would ultimately
improve cell survival after implantation. To test this hypothe-
sis, we transfected the ILK gene into MSCs (ILK-MSCs) and
analyzed their adhesion under hypoxic conditions. Moreover,
we implanted ILK-MSCs into infarcted myocardium and
examined the resulting physiological and morphological
changes in the implanted heart tissue.
MATERIALS AND METHODS
Isolation and Culture of MSCs
MSCs were isolated from the femoral and tibial bones of rats.
Bone marrow-derived MSCs were collected from the aspirates of
femurs and tibias from 4-week-old male Sprague-Dawley rats
(approximately 100 g) with 10 ml of MSC medium comprising
Dulbecco’s modiﬁed Eagle’s medium (DMEM)-low glucose sup-
plemented with 10% fetal bovine serum (FBS) and a 1% antibi-
otic-penicillin and streptomycin solution. Flushed media were
centrifuged at 1,600 rpm, 5 minutes and resuspended in serum-
supplemented medium, next loaded to Percoll density gradient
centrifugation at 1,600 rpm, 30 minutes. Mononuclear cells were
recovered from the middle interface after centrifugation in Per-
coll, were washed twice, resuspended in 10% FBS-DMEM, and
plated in ﬂasks at a density of 1  106 cells per 100 cm2. Cul-
tures were maintained at 37C in a humidiﬁed atmosphere con-
taining 5% CO2. After 48 or 72 hours, nonadherent cells were
discarded and the adherent cells were thoroughly washed twice
with phosphate-buffered saline (PBS). Fresh complete medium
was added and replaced every 3 or 4 days for approximately
10 days. To further purify the MSCs, we used the Isolex Mag-
netic Cell Selection System (Baxter Healthcare Corporation,
Irvine, CA, http://www.baxter.com). Brieﬂy, cells were incubated
with Dynabeads M-450 coated with anti-CD34 monoclonal anti-
body. A magnetic ﬁeld was applied to the chamber and the
CD34þ cell-bead complexes were separated magnetically from
the remaining cell suspension. The CD34-negative fraction was
then cultured further. After incubation, the cells were harvested
with 0.25% trypsin and 1 mM EDTA for 5 minutes at 37C,
replated in 1  105/100 cm2 plates, and grown for approximately
10 days. The characteristics of MSCs were demonstrated by
immunophenotyping. To verify the nature of cultured MSCs, cells
were labeled against various surface and intracellular markers,
and analyzed by ﬂow cytometry. Cells were harvested, washed
with PBS, and labeled with the following antibodies conjugated
with ﬂuorescein isothiocyanate (FITC) or Texas red: CD14,
CD34, CD71, CD90, CD105, and ICAM-1. FITC-conjugated goat
anti-mouse IgG and Texas red-conjugated goat anti-rabbit IgG
from Jackson ImmunoResearch Laboratories (West Grove, PA,
http://www.jacksonimmuno.com) were used as secondary antibod-
ies. Labeled cells were assayed by ﬂow cytometry and analyzed
with CellQuest Pro Software (BectonDickinson, San Jose, CA,
http://www.bd.com). MSC were lentivirally transduced at second
passage and used for in vitro and in vivo experiments between
passage 4 and 6.
Lentiviral Vector-Mediated Stable Genetic
Modiﬁcation of MSCs
For stable genetic modiﬁcation, we used a lentiviral vector (Len-
tiV) for transgene delivery. The LentiV harboring ILK gene with
mCMV promoter and green ﬂuorescent protein (GFP) gene with
pgk promoter was constructed by inserting the gene fragment into
the EcoR I- Cla I site of the LentiV (Marcrogen, Seoul, Korea,
http://www.macrogen.co.kr) and was obtained commercially. The
ILK (BC001554) cDNA clone was purchased from Korean Bio-
information Centor and the cDNA was ampliﬁed using the
following primer set: Forward: 50-gggaattcgccaccatggacgacatt-30,
Reverse: 50-attatcgattcctacttgtc-30. The nucleotide sequences of
the constructs were veriﬁed by sequencing analysis. Passage-2
MSCs were plated at a concentration of 2  105 cells per well in
12-well plates. MSCs were transduced by adding puriﬁed LentiVs
to the cells in the presence of 8 lg/ml of polybrene at MOIs of
50 in 250 ll of medium (to facilitate transduction). At approxi-
mately 20 hours after transduction, the virus-containing medium
was removed and replaced with fresh MSC complete medium.
Immunoblot Analysis
Cells were washed once in PBS and lysed in lysis buffer (Cell
Signaling Technology, Beverly, MA, http://www.cellsignal.com)
containing 20 mM Tris (pH 7.5), 150 mM NaCl, 1 mM Na2-
EDTA, 1 mM EGTA, 1% Triton, 2.5 mM sodium pyrophosphate,
1 mM b-glycerophosphate, 1 mM Na3VO4, 1 mg/ml leupeptin,
and 1 mM phenylmethylsulfonyl ﬂuoride. Protein concentrations
were determined using the Bradford Protein Assay Kit (Bio-Rad,
Hercules, CA, http://www.bio-rad.com). Proteins were separated
in a 12% sodium dodecyl sulfate-polyacrylamide gel and trans-
ferred to a polyvinylidene diﬂuoride membrane (Millipore, Biller-
ica, MA, http://www.millipore.com). After blocking the mem-
brane with Tris-buffered saline-Tween 20 (TBS-T; 0.1% Tween
20) and 5% nonfat dried milk for 1 hour at room temperature, the
membrane was washed twice with TBS-T and incubated with pri-
mary antibody for 1 hour at room temperature or overnight at
4C. Next, the membrane was washed three times with TBS-T
for 10 minutes and incubated for 1 hour at room temperature
with horseradish peroxidase-conjugated secondary antibodies. Af-
ter extensive washing, the bands were detected with an enhanced
chemiluminescence reagent (Santa Cruz Biotechnology, Santa
Cruz, CA, http://www.scbt.com). The band intensities were quan-
tiﬁed using a Photo-Image System (Molecular Dynamics, Sunny-
vale, CA, http://www.mdyn.com). Expression and phosphoryla-
tion of proteins was normalized to b-actin and expression levels,
respectively.
Cell Survival
Cell survival was measured with the PreMix WST-1 Cell Count-
ing System (TAKARA BIO, Shiga, Japan, http://www.takara-bio.
com). This system enables the measurement of cell survival with
a colorimetric assay that is based on the cleavage of slightly red
tetrazolium salt (WST-1) by mitochondrial succinate-tetrazolium
reductase in viable cells. An increase in enzyme activity leads to
an increase in the production of formazan dye, thus the quantity
of formazan dye is related directly to the number of metabolically
active cells in the medium. Wells of a 96-well culture plate were
seeded with 2  104 cells and incubated under hypoxic condi-
tions after transduction of the LentiV. The WST-1 cell counting
reagent was added directly to the supernatant (10 ll/100 ll
growth medium) and incubated at 37C for 3 hours. We then
determined the absorbance of the solubilized dark red formazan
product at 450 nm.
Measurement of Caspase-3 Activity
Relative caspase-3 activity was determined using the ApopTar-
getTM Capase-3 Colorimetric Protease Assay according to the
manufacturer’s instructions (BioSource International, Grand
Island, NY, http://www. invitrogen.com). This assay is based on
the generation of free Asp-Glu-Val-Asp (DEVD)-p-nitroanilide
(pNA) chromophore when the provided substrate is cleaved by
caspase-3. On cleavage of the substrate by Caspase-3, free pNA
light absorbance at 405 nm can be quantiﬁed using a microplate
reader. After different treatments, the cultured MSCs (2  106)
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were harvested in lysis buffer (1 M dithiothreitol) and the cell
extracts were centrifuged to eliminate cellular debris. Fifty micro-
liter aliquots of the cell extracts were incubated at 37C for 2
hours in the presence of the chromophore substrate. Free DEVD-
pNA was then determined colometrically. By comparing the ab-
sorbance of pNA from apoptotic samples with uninduced con-
trols, we could determine the fold increase in capase-3 activity.
Data denote means  SEM of two to three replicate measure-
ments in three different cell cultures.
Preparation of Cardiac Fibroblast-Derived
Three-Dimensional Matrix (Cardiogel)
Cardiogel was prepared with a minor modiﬁcation [17]. Brieﬂy,
2  105 cells (cardiac ﬁbroblast) per 35-mm dish were seeded and
the medium changed every 48 hours until the matrix prepared.
About 4 days, cells were in full conﬂuence. The medium was
carefully aspirated and rinsed gently with PBS. Next, 1 ml of pre-
warmed extraction buffer (0.5% Triton X-100, 20 mM NH4OH in
PBS) was added and the process of cell lysis was observed using
an inverted microscope until no intact cells were visualized. The
cellular debris was washed with PBS and the matrices were incu-
bated at 37C for 30 minutes with 1 ml of DNase (10 units of
DNase per milliliter of PBS) to minimize the DNA debris. For
later use, the matrix-coated plates were covered with a minimum
of 3 ml of PBS containing 100 U/ml penicillin, 100 lg/ml strep-
tomycin, and 0.25 lg/ml Fungizone.
Assay for Cell Adhesion
Assay for cell adhesion was achieved in compliance with our pre-
vious study [17]. ILK-MSCs or untransfected control MSCs were
isolated by trypsinization, washed once in DMEM with 10% FBS
to stop the trypsin activity, and then washed twice with serum-
free DMEM to remove the serum components. Suspensions of
2  104 viable MSCs were then added to each well and allowed
to attach for 30 minutes at 37C under 5% CO2. To quantify
MSC adhesion, the plates were carefully washed three times with
PBS and then four separate ﬁelds were photographed by phase
contrast microscope. The number of attached cells was estimated
by counting the number of cells using a hemacytometer under a
microscope. Each experiment was performed in triplicate wells
and repeated at least three times. Number of attached cells was
calculated by subtracting the number of rinsed cells from number
of seeded cells.
Induction of MI and Transplantation
All experimental procedures for animal studies were approved by
the Committee for the Care and Use of Laboratory Animals, Yon-
sei University College of Medicine, and performed in accordance
with the Committee’s guidelines and regulations for animal care.
MI was produced in male Sprague-Dawley rats (200  30 g) by
surgical occlusion of the left anterior descending coronary artery,
according to previously described procedures [17]. Brieﬂy, after
induction of anesthesia with ketamine (10 mg/kg) and xylazine (5
mg/kg), the third and fourth ribs were cut to open the chest, and
the heart was exteriorized through the intercostal space. The left
coronary artery was ligated 2–3 mm from its origin with a 5-0
prolene suture (ETHICON, Somerville, NJ, http://www.
ethicon.com) for 3 days. For transplantation, cells were suspended
in 10 ll of serum-free medium (1  106 cells) and injected at
three injection sites into anterior and lateral aspects of the viable
myocardium bordering the infarction with a Hamilton syringe
(Hamilton, Reno, NV, http://www.hamiltoncompany.com) with a
30-gauge needle. Cells were kept on ice prior to injection for pre-
venting cell damage. Throughout the operation, animals were
ventilated with 95% O2 and 5% CO2 using a Harvard ventilator.
The operative mortality was 10% within 48 hours. Six animals
per group (ligation, MSCs, and ILK-MSCs) were used for mor-
phologic analysis at 1 week after occlusion of the left coronary
artery. To investigate the adhesion degree of cell containing ILK
gene in vivo, we used six animals per group at 3 days after
occlusion.
Histology and Determination of the Area of Fibrosis
At several intervals (3 or 7 days) after implantation, animals
were killed and their hearts were excised. Each heart was perfu-
sion-ﬁxed with 10% (v/v) neutral-buffered formaldehyde for
24 hours, transversely sectioned into four comparably thick sec-
tions, and embedded in parafﬁn by routine methods. Sections of
2 lm thickness were mounted on gelatin-coated glass slides to
ensure that different stains could be used on successive tissue sec-
tions cut through the implantation area. After deparafﬁnization and
rehydration, the sections were stained with hematoxylin and eosin
to assess cytologic details such as nuclei, cytoplasm, and connec-
tive tissue. Additionally, ﬁbrosis was analyzed by Masson’s Tri-
chrome staining. The interstitial ﬁbrosis areas were measured from
control (n ¼ 6), MI (n ¼ 6), MI þ MSCs (n ¼ 6), MI þ ILK 
MSCs (n ¼ 6) groups using MetaMorph software version 4.6 (Uni-
versal Imaging, Downingtown, PA, http://www.universal-imaging.
com), and expressed as a percentage of the total LV.
Terminal Deoxynucleotidyl Transferase-Mediated
dUTP Nick-End Labeling Assay
The terminal deoxynucleotidyl transferase-mediated dUTP nick
end labeling (TUNEL) assay was performed according to the
manufacturer’s instructions (Chemicon International, Temecula,
CA, http://www.chemicon.com). In brief, excised heart tissues
were ﬁxed in 3.7% buffered formaldehyde and embedded in par-
afﬁn. Tissue sections, 5-lm thick, were deparafﬁnized, rehy-
drated, and rinsed with PBS. A positive control sample was pre-
pared from a normal heart section by treating the section with
DNase I (10 U/ml, 10 minutes at room temperature). The sections
were pretreated with 3.0% H2O2, subjected to terminal deoxynu-
cleotidyl transferase enzyme for 37C for 1 hour, and incubated
digoxigenin-conjugated nucleotide substrate at 37C for 30
minutes. Nuclei exhibiting DNA fragmentation were visualized
by adding 3,3-diamino benzidine (DAB; Vector Laboratories,
Burlingame, CA, http://www.vectorlabs.com) for 5 minutes. The
nuclei of apoptotic cardiomyocytes were stained dark brown.
Lastly, sections were counterstained with methyl green. A cover-
slip was place on top of each section and the sections were
observed by light microscopy. For each group, six slices were
prepared and 10 different regions were observed in each slice
(400)
Determination of Infarct Size
2,3,5-Triphenyltetrazolium chloride (TTC) staining was used to
assess myocardial tissue viability and determine the size of the
myocardial infarct. The tissue slices were incubated in a 1% TTC
(Sigma, St. Louis, MO, http://www. sigma.com) solution, pH 7.4,
at 37C for 20 minutes. The tissues were ﬁxed in 10% PBS-buf-
fered formalin overnight at 2C–8C. The hearts were sectioned
transaxially and the size of the MI was evaluated as a percentage
of the sectional area of the infarcted tissue of the LV to the sec-
tional area of the whole LV. Both sides of each TTC-stained tis-
sue slice were photographed with a digital camera.
Determination of Capillary Density
Histological analysis was performed according to the instructions
of the manufacturer (R.T.U VECTASTAIN Universal Quick Kit;
Vector Laboratories). In brief, the excised heart tissues were ﬁxed
in 3.7% buffered formaldehyde and embedded in parafﬁn. Tissue
sections, 5-lm thick, were deparafﬁnized, rehydrated, and rinsed
with PBS. Antigen retrieval was performed with 10 mM sodium
citrate (pH 6.0) in microwave for 10 minutes. Sections were incu-
bated in 3% H2O2 to quench endogenous peroxidase. Sample was
blocked in 2.5% normal horse serum, and incubated in anti-CD31
antibody. Biotinylated pan-speciﬁc universal secondary antibody
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and streptavidin/peroxidase complex reagent was used to treat the
heart sections. Using the DAB substrate kit, the heart sections
were stained with antibody. Counterstaining was performed with
1% methyl green and dehydration was progressed with 100% N-
butanol, ethanol, and xylene before mounting in VectaMount
Mounting Medium (Vector Laboratories). For quantiﬁcation,
capillaries were counted in 10 randomly chosen ﬁelds from two
separate slides using the (20) objective. The mean number of
capillaries per ﬁeld in the infarcted myocardium was used for sta-
tistical analysis.
Statistical Analysis
Data are expressed as means  SE. Statistical comparisons
between the two groups were performed using the Student’s t
test. In addition, a one-way analysis of variance using a Bonfer-
roni test was used when comparing more than two groups. A p
value <.05 was considered signiﬁcant.
RESULTS
Expression and Survival of ILK-MSCs in
Hypoxic Condition
MSCs were ﬁrst isolated from mixed culture with hematopoietic
cells based on their attachment to the culture plate, and the iso-
lated MSCs were further puriﬁed by exclusion using magnetic
beads targeting the hematopoietic marker CD34, yielding 3 
106 cells (95% purity) after 2 weeks of culture. Consistent with
the previous report the cultured MSCs expressed CD71, CD90,
CD105, CD106, and ICAM, but the hematopoietic marker
CD34 and CD14 were not expressed (data not shown) [17].
Hypoxia facilitates disruption of tissue integrity, which leads
to cellular anoikis. During the 24 hours after hypoxic stress,
endogenous ILK expression in MSCs was time-dependently
Figure 1. Expression and survival of ILK-MSCs in hypoxic condition. (A): Expression of ILK in MSCs under hypoxic conditions was moni-
tored by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) followed by immunoblot analysis (*, p < .001). (B): Cell pro-
liferation under hypoxic conditions for 9 hours was measured by WST-1 Cell Proliferation Assay System (k ¼ 570 nm; *, p < .001). (C):
Effects of ILK on the activity of survival-related proteins under hypoxic conditions were monitored by SDS-PAGE with antibodies speciﬁc for
ILK, ERK1/2, p-ERK1/2, Akt, p-Akt, and b-actin (*, p < .001). Band intensities were quantiﬁed using the Photo-Image System; each point repre-
sents the mean value obtained from three experiments. Abbreviations: ILK-MSCs, integrin-linked kinase-transfected MSCs; MSCs, mesenchymal
stem cells; p-Akt, phosphorylated Akt; p-ERK, phosphorylated ERK.
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downregulated by Western blot analysis (Control vs. Hypoxia
9h: 3.62  0.27 vs. One.41  0.05, p < .001; Control vs. Hy-
poxia 24h: 3.62  0.27 vs. 0.51  0.01, p < .001; Fig. 1A).
MSCs were transduced with LentiV harboring ILK gene and a
signiﬁcant dose-response was observed with increasing virus ti-
ter for MOI 1 to 50. Transduction efﬁciency was a maximum of
94% at MOIs of 50. To deﬁne the effect of ILK on MSC sur-
vival in hypoxic conditions, ILK-MSCs were incubated under
hypoxic conditions for 9 hours and cell viability was then deter-
mined by a WST-1 assay. As shown in Figure 1B, ILK overex-
pression enhanced the survival rate of MSCs by about 50% com-
pared with Mock-MSCs (Control vs. mock-MSC: 1.09  0.05
vs. 0.49  0.03, p < .001; ILK-MSC vs. mock-MSC: 0.86 
0.05 vs. 0.49  0.03, p < .001). Hypoxic ILK-MSCs had a
threefold increase in ERK1/2 activity (control vs. MSC: 3.11 
0.16 vs. 0.81  0.10, p < .001; ILK-MSC vs. MSC: 2.41  0.27
vs. 0.81  0.10, p < .001) and a twofold increase in Akt activity
compared with nontransformed hypoxic MSCs (control vs.
MSC: 3.20  0.22 vs. 0.79  0.11, p < .001; ILK-MSC vs.
MSC: 1.75  0.21 vs. 0.79  0.11, p < .001; Fig. 1C).
Effect of ILK on Hypoxia-Induced MSC Anoikis
To determine the effect of ILK overexpression on MSC adhe-
sion, we performed quantitative adhesion assays with ILK-
MSCs. Adhesion of MSCs to a three-dimensional culture sys-
tem derived from cardiac ﬁbroblasts was enhanced by twofold
with the introduction of ILK (ILK-MSC vs. MSC: 62.7% 
0.6% vs. 30.5%  0.5%, p < .01; Fig. 2A). To further evalu-
ate the adhesive function of ILK in vivo, we transplanted
ILK-MSCs into the border region of infarcted hearts. ILK-
MSCs had an approximate retention rate of 800 cells per sec-
tion, while the control MSCs had a retention rate of approxi-
mately 200 cells per section (ILK-MSC vs. MSC: 758  40
vs. 218  9, p < .01; Fig. 2B). To examine whether ILK
expression of MSCs inhibits apoptosis in hypoxic conditions,
we examined the ratio of Bcl-2/Bax as well as caspase-3 acti-
vation. As shown in Figure 2C, ILK overexpression signiﬁ-
cantly reduced the caspase-3 activity by 42.4% compared
with Mock-MSCs (control vs. Mock-MSC: 1.03  0.14 vs.
Three.52  0.18, p < .001; ILK-MSC vs. Mock-MSC:
Figure 2. Effect of ILK on hypoxia-induced MSCs anoikis. (A): Effect of ILK on MSC adhesion was examined with a cardiogel for 3 hours.
The mean attachment values  SD on the cardiogel were 6,102  98 in MSCs and 12,541  120 in ILK-MSCs (*, p < .01). (B): Analysis of
myocardial repair after implantation into an infarcted myocardium was operated with GFP expression. Engraftment was signiﬁcantly improved
with ILK overexpression 3 days after the cells were injected (1  106; *, p < .01). Each value is the mean  SEM of six independent experi-
ments. (C): Relative caspase-3 activity was determined using the ApopTarget Capase-3 Colorimetric Protease Assay (*, p < .001). (D): Expres-
sion of Bcl-2 and Bax were determined by immunoblot analysis in ILK-MSCs or MSCs that were incubated in hypoxic conditions for 9 hours
(*, p < .001, **, p < .01). Abbreviations: GFP, green ﬂuorescent protein; ILK-MSCs, integrin-linked kinase-transfected MSCs; MSCs, mesenchy-
mal stem cells.
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2.03  0.08 vs. Three.52  0.18, p < .001). The ILK-MSCs in
the hypoxic condition induced an increased Bcl-2/Bax ratio of
about twofold when compared with the control MSCs (control
vs. MSC: 3.14  0.18 vs. 0.59  0.09, p < .001; ILK-MSC vs.
MSC: 1.52  0.15 vs. 0.59  0.09, p < .01; Fig. 2D).
Effect of Transplantation of ILK-MSCs
Following Acute MI
We determined the infarct sizes in the LV using TTC staining
(n ¼ 6 rat/group). Injection of MSCs resulted in a signiﬁcant
decrease in infarct size, and injection of MSC-ILKs further
reduced the infarct size (Sham vs. MSC: 28.2%  5.5% vs.
17%  1.2%, p < .05; ILK-MSC vs. MSC: 5%  1.9% vs.
17%  1.2%, p < .01; Fig. 3A). Transplantation of ILK-MSCs
signiﬁcantly decreased interstitial ﬁbrosis to 2.5%  1.0%.
Namely, the specimens with ILK-MSC injected-ischemic myo-
cardium showed decreased ﬁbrosis in the LV and a thicker wall
compared with the ligation controls and the MSC-injected
hearts (Sham vs. ILK-MSC: 18.5%  1.4% vs. 2.5%  1.0%,
p < .01; MSC vs. ILK-MSC: 8.3%  1.7% vs. 2.5%  1.0%,
p < .01; Fig. 3B). The incidence of TUNEL-positive myocar-
dial cells caused by ligation was reduced by two-thirds in the
ligated hearts transplanted with ILK-MSCs when compared
with sham and was one-third lower than MSC injected hearts
(Sham vs. ILK-MSC: 28.3%  1.8% vs. 10.1%  0.2%, p <
.05; MSC vs. ILK-MSC: 15.3%  0.7% vs. 10.1%  0.2%,
p < .05; Fig. 3C). The mean microvessel count per ﬁeld in the
infarcted myocardium was signiﬁcantly higher in the ILK-MSC
group than in the sham and MSCs group (Sham vs. ILK-
MSC: 19.3  15.2 vs. 129.1  23.5, p < .01; MSC vs. ILK-
MSC: 68.9  19.4 vs. 129.1  23.5, p < .05; Fig. 3D).
DISCUSSION
Cell implantation utilizing cardiac stem cells [18], embryonic
stem cells [19], hematopoietic stem cells [20], MSCs [21–23],
skeletal myoblasts [24–26], and cardiac myocytes (adult, fetal,
or neonatal myocytes) [27, 28] has been suggested to be a
promising clinical approach for restoration of myocardial
function after cardiac infarction. Among these various candi-
date cell types, MSCs have a great advantage with respect to
generating functional cardiac myocytes in the infarcted myo-
cardium because of their ease of preparation and potential to
differentiate into a cardiac lineage [29, 30] both in vivo and
in vitro under appropriate culture conditions. In addition, the
delivered MSCs have clearly improved the physiological
functions of the infarcted heart by limiting infarct size and
preserving at-risk regions [31, 32].
Although MSCs represent a suitable source of autologous
cells in cell therapy for the improvement of cardiac function,
MSC therapy has limitations due to the poor viability of
MSCs after cell transplantation [7]. Thus, to improve the efﬁ-
cacy of cell therapy, it is necessary to protect MSCs from
anoikis resulting from hypoxic conditions by genetic modiﬁ-
cation. Recently, in a new approach to enhance the viability
of MSCs, they were transduced with the gene for the survival
signal, Akt, prior to transplantation [33]. On the basis of our
previous study, the absence of adhesion is probably the main
cause of poor cell survival after cell transplantation [17].
The purpose of the in vitro section of our study was to con-
ﬁrm the role of ILK on MSC adhesion and the effect of ILK on
cellular survival signals. On the basis of our observation, our
data showed that hypoxic surroundings supressed expression of
the ILK protein which interacts with the b1-subunit of integrin
and plays a crucial role in integrin-mediated cell adhesion and
Figure 3. Effect of transplantation of ILK-MSCs following acute
myocardial infarction (MI). (A): Intramyocardial injection of MSCs
reduced the LV infarct size as assessed by 2,3,5-triphenyltetrazolium
chloride staining at 1 week post-MI. ILK-MSCs further decreased the
area of necrotic tissue (*, p < .01; **, p < .05). (B): The left panel
shows representative Masson’s trichrome images from histological
sections and the right histogram shows ﬁbrosis (blue) ratio of each
heart at 1 week post-MI (*, p < .01). (C): An apoptosis assay was
performed on heart tissue at 1 week after the ligation of LAD. The
left panel shows representative images of the Terminal deoxynucleoti-
dyl Transferase-mediated dUTP nick-end labeling staining (original
magniﬁcation 200). Staining for normal nuclei (green) was carried
out using methyl green while apoptotic nuclei were stained brown.
The right panel shows the summarized data from left panel (*, p <
.05). (D): Quantitative analysis showed that microvessel density was
signiﬁcantly higher in ILK-MSCs groups than in MSC and sham
groups at 1 week post-MI (*, p < .01, **, p < .05). The arrowheads
indicate the representative CD31-positive microvessels. Brown: posi-
tively stained for CD31. Each value is the mean  SEM of six inde-
pendent experiments. Abbreviations: Abbreviations: ILK-MSCs,
integrin-linked kinase-transfected MSCs; LV, left ventricle; MSCs,
mesenchymal stem cells.
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signaling [10, 11]. In addition, we observed that transfection
with the ILK gene enhanced phosphorylation of ERK and Akt,
proteins which plays a critical role in regulation of adhesion-
mediated cell survival signals in hypoxic MSCs. We also con-
ﬁrmed an increase in the Bcl-2/Bax ratio and an inhibition of
caspase-3 activation. These data suggested that ILK gene pro-
moted cell adhesion in hypoxic condition, which avoided cell
apoptosis. Cell-ECM adhesion is crucial for the control of cell
behavior. Adhesion of cells to the ECM stimulates signal trans-
duction cascades that are involved in proliferation, migration,
differentiation, and even survival [12, 34–37]. In particular, an-
chorage-dependent cells depend on interactions between integ-
rins and the ECM for survival. Namely, the interaction of mes-
enchymal as well as epithelial and endothelial cells with the
ECM inhibits default apoptotic pathways, which become acti-
vated if cell-ECM interactions are disrupted. This type of sus-
pension-induced apoptosis is termed anoikis [38, 39]. ILK
enhances phosphorylation of PKB/Akt, which plays a critical
role in regulation of adhesion-mediated cell survival signals. In
addition, Danielle et al. reported that ILK was involved in regu-
lation of anoikis in human MSCs [40]. Therefore, ILK func-
tions as an important mediator in the signal transduction from
the ECM, thus regulating adhesion-dependent cell signaling
and the apoptotic pathway. According to our in vivo histologi-
cal ﬁndings, transplantation of ILK-MSCs resulted in a further
decrease in infarct size and a further improvement in LV func-
tion compared to the MSC group. Moreover, the improved
microvessel density was closely correlated with the presence of
ILK-MSCs in the infarcted area.
CONCLUSION
Although MSCs represent a suitable source of autologous
cells for cell therapy targeted to improve cardiac function,
MSC therapy has limitations due to the poor viability of
MSCs after cell transplantation. Integrin-mediated adhesion
is a prerequisite for cell survival and also a key factor for
the differentiation of MSCs. As a novel antideath strategy
to improve stem cell survival/number in the infarcted heart,
we genetically engineered MSCs to overexpress ILK to
enhance adhesion and ultimately increase cell survival after
implantation. Genetic modiﬁcation of MSCs with ILK
enhanced cell adhesion, survival rates, and cell adhesion-
related signaling in vitro. ILK-MSCs further improved the
cardiac function of infarcted myocardium when compared
with myocardium that had been transplanted with MSCs
alone. These ﬁndings suggested that genetic modiﬁcation of
MSCs might be an effective therapeutic approach for treat-
ing infarcted myocardium.
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